Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on November 4, 2015. The report details the entry into a Material Definitive Agreement regarding the company's securitization facility.
Key Financial Metrics and Liquidity
The filing focuses on liquidity arrangements rather than operational performance metrics such as revenue or profit.
- Facility Type: Securitization facility based on accounts receivables from pharmaceutical sales.
- Base Limit: $950 million.
- Seasonal Expansion: Option to increase commitments by an additional $250 million during December and March quarters, subject to bank approval.
- Guarantor: AmerisourceBergen Corporation serves as the performance guarantor for the obligations of its subsidiary, AmerisourceBergen Drug Corporation (ABDC).
Material Changes
On November 4, 2015, the company executed an Omnibus Amendment to its existing Receivables Purchase Agreement and Receivables Sale Agreement. Key changes include:
- Extension of Term: The scheduled termination date of the securitization facility was extended from December 5, 2017, to November 2, 2018.
- Asset Scope Expansion: Accounts receivable from Bellco Drug Corp. (a wholly-owned subsidiary) are now eligible to be included in the calculation of "Receivables" following the transfer of Bellco's assets and liabilities to ABDC.
- Technical Adjustments: Certain technical changes were made to the agreements.
- Verify the effective date of the Bellco Drug Corp. asset transfer to confirm when its receivables become eligible for the facility.
- Confirm the current utilization rate of the $950 million base limit and any seasonal drawdowns.
- Review the specific "technical changes" in the Omnibus Amendment (Exhibit 10.1) for potential covenant modifications.
- Monitor the approval status of the optional $250 million seasonal increase for upcoming quarters.
Outlook and Management Commentary
The amended facility is intended to provide additional liquidity and funding for the ongoing business needs of the Registrant and its subsidiaries. The filing does not contain forward-looking guidance on revenue, earnings, or broader market outlooks, nor does it disclose specific risks beyond the standard terms of the amended agreement.